Advertisement

Circulating Tumor Cells (CTCs) and Metastatic Prostate Cancer (mPCa)

  • Elisabetta RossiEmail author
  • Rita Zamarchi
Chapter

Abstract

The great advances in mPCa management recently obtained with the second-line treatments have highlighted the need to identify and exploit surrogate endpoints for survival of patients and effectiveness of treatment. These surrogate endpoints could be also used to reduce size and costs of pivotal trials of new molecules and the time from the benchtop to the patients’ bedside. A large consensus is emerging in the scientific community that circulating tumor cells (CTCs) meet the criteria required for a surrogate endpoint, particularly in mPCa.

The main open question about the clinical management of mPCa is discussed, with the intent to underscore how the extended use of CTC detection and characterization can offer further benefit to these patients.

Keywords

Overall Survival Androgen Receptor Radical Prostatectomy Circulate Tumor Cell Androgen Receptor Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hayes DF (2015) Biomarker validation and testing. Mol Oncol 9(5):960–966CrossRefPubMedGoogle Scholar
  2. 2.
    Zhang T, Armstrong AJ (2016) Clinical utility of circulating tumor cells in advanced prostate cancer. Curr Oncol Rep 18(1):3CrossRefPubMedGoogle Scholar
  3. 3.
    De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E et al (2014) Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE – 5-a population-based study. Lancet Oncol 15(1):23–34CrossRefPubMedGoogle Scholar
  4. 4.
    Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, Nordling S, Haggman M, Andersson SO, Spangberg A et al (2014) Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 370(10):932–942CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Luengo-Fernandez R, Leal J, Gray A, Sullivan R (2013) Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 14(12):1165–1174CrossRefPubMedGoogle Scholar
  6. 6.
    Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10(20):6897–6904CrossRefPubMedGoogle Scholar
  7. 7.
    Moreno JG, O’Hara SM, Gross S, Doyle G, Fritsche H, Gomella LG, Terstappen LW (2001) Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology 58(3):386–392CrossRefPubMedGoogle Scholar
  8. 8.
    Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M et al (2007) Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13(23):7053–7058CrossRefPubMedGoogle Scholar
  9. 9.
    de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14(19):6302–6309CrossRefPubMedGoogle Scholar
  10. 10.
    Lawrentschuk N, Haider MA, Daljeet N, Evans A, Toi A, Finelli A, Trachtenberg J, Zlotta A, Fleshner N (2010) ‘Prostatic evasive anterior tumours’: the role of magnetic resonance imaging. BJU Int 105(9):1231–1236CrossRefPubMedGoogle Scholar
  11. 11.
    Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH et al (1977) Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 20(5):680–688CrossRefPubMedGoogle Scholar
  12. 12.
    Nelson WG, De Marzo AM, Isaacs WB (2003) Prostate cancer. N Engl J Med 349(4):366–381CrossRefPubMedGoogle Scholar
  13. 13.
    Leitzmann MF, Rohrmann S (2012) Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol 4:1–11CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Richman EL, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM (2011) Egg, red meat, and poultry intake and risk of lethal prostate cancer in the prostate-specific antigen-era: incidence and survival. Cancer Prev Res (Phila) 4(12):2110–2121CrossRefGoogle Scholar
  15. 15.
    Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, Bedrosian I, Kuerer HM, Krishnamurthy S (2012) Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 13(7):688–695CrossRefPubMedGoogle Scholar
  16. 16.
    Rack B, Schindlbeck C, Juckstock J, Andergassen U, Hepp P, Zwingers T, Friedl TW, Lorenz R, Tesch H, Fasching PA et al (2014) Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 106(5)Google Scholar
  17. 17.
    Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353(8):793–802CrossRefPubMedGoogle Scholar
  18. 18.
    Davis JW, Nakanishi H, Kumar VS, Bhadkamkar VA, McCormack R, Fritsche HA, Handy B, Gornet T, Babaian RJ (2008) Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol 179(6):2187–2191; discussion 2191CrossRefPubMedGoogle Scholar
  19. 19.
    Rossi E et al (2015) AACR Annu Meet poster #379Google Scholar
  20. 20.
    Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H (2001) Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 165(4):1146–1151CrossRefPubMedGoogle Scholar
  21. 21.
    Armstrong AJ, Eisenberger MA, Halabi S, Oudard S, Nanus DM, Petrylak DP, Sartor AO, Scher HI (2012) Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol 61(3):549–559CrossRefPubMedGoogle Scholar
  22. 22.
    Denham JW, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, Matthews J, Tai KH, Spry NA, Christie D et al (2008) Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial. Lancet Oncol 9(11):1058–1068CrossRefPubMedGoogle Scholar
  23. 23.
    Ray ME, Bae K, Hussain MH, Hanks GE, Shipley WU, Sandler HM (2009) Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. J Natl Cancer Inst 101(4):228–236CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Mehra N, Zafeiriou Z, Lorente D, Terstappen LW, de Bono JS (2015) CCR 20th anniversary commentary: circulating tumor cells in prostate cancer. Clin Cancer Res 21(22):4992–4995CrossRefPubMedGoogle Scholar
  25. 25.
    Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA et al (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32(11):1136–1142CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB et al (2015) SWOG S0925: a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. J Clin Oncol 33(14):1601–1608CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Thalgott M, Heck MM, Eiber M, Souvatzoglou M, Hatzichristodoulou G, Kehl V, Krause BJ, Rack B, Retz M, Gschwend JE et al (2015) Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy. J Cancer Res Clin Oncol 141(8):1457–1464CrossRefPubMedGoogle Scholar
  28. 28.
    Scher HI, Heller G, Molina A, Attard G, Danila DC, Jia X, Peng W, Sandhu SK, Olmos D, Riisnaes R et al (2015) Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol 33(12):1348–1355CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Fleisher M et al (2015) J Clin Oncol 33(suppl; abstr 5035)Google Scholar
  30. 30.
    Ashworth TR (1869) A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J 14:146Google Scholar
  31. 31.
    De Morgan C (1874) Observations on cancer: its pathology, and its relations to the organism and to other morbid growths. Lancet 103(2636):325–329CrossRefGoogle Scholar
  32. 32.
    Paget S (1889) The distribution of secondary growths in cancer of the breast. 1989. Cancer Metastasis Rev 8(2):98–101Google Scholar
  33. 33.
    Pool EH, Dunlop GR (1934) Cancer cells in the blood stream. Am J Cancer 21:99–102CrossRefGoogle Scholar
  34. 34.
    Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781–791CrossRefPubMedGoogle Scholar
  35. 35.
    Braun S, Cevatli BS, Assemi C, Janni W, Kentenich CR, Schindlbeck C, Rjosk D, Hepp F (2001) Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol 19(5):1468–1475PubMedGoogle Scholar
  36. 36.
    Bidard FC, Peeters DJ, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J et al (2014) Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 15(4):406–414CrossRefPubMedGoogle Scholar
  37. 37.
    Saucedo-Zeni N, Mewes S, Niestroj R, Gasiorowski L, Murawa D, Nowaczyk P, Tomasi T, Weber E, Dworacki G, Morgenthaler NG et al (2012) A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol 41(4):1241–1250PubMedPubMedCentralGoogle Scholar
  38. 38.
    Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K, Capron F, Franco D, Pazzagli M, Vekemans M et al (2000) Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 156(1):57–63CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    de Wit S, van Dalum G, Lenferink AT, Tibbe AG, Hiltermann TJ, Groen HJ, van Rijn CJ, Terstappen LW (2015) The detection of EpCAM(+) and EpCAM(-) circulating tumor cells. Sci Rep 5:12270CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Gupta V, Jafferji I, Garza M, Melnikova VO, Hasegawa DK, Pethig R, Davis DW (2012) ApoStream(™), a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood. Biomicrofluidics 6(2):24133CrossRefPubMedGoogle Scholar
  41. 41.
    Bolognesi C, Forcato C, Buson G, Fontana F, Mangano C, Doffini A, Sero V, Lanzellotto R, Signorini G, Calanca A et al (2016) Digital sorting of pure cell populations enables unambiguous genetic analysis of heterogeneous formalin-fixed paraffin-embedded tumors by next generation sequencing. Sci Rep 6:20944CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Janicke F et al (2007) Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clin Cancer Res 13(3):920–928CrossRefPubMedGoogle Scholar
  43. 43.
    Kraan J, Sleijfer S, Strijbos MH, Ignatiadis M, Peeters D, Pierga JY, Farace F, Riethdorf S, Fehm T, Zorzino L et al (2011) External quality assurance of circulating tumor cell enumeration using the Cell Search((R)) system: a feasibility study. Cytometry B Clin Cytom 80(2):112–118CrossRefPubMedGoogle Scholar
  44. 44.
    Cummings J, Morris K, Zhou C, Sloane R, Lancashire M, Morris D, Bramley S, Krebs M, Khoja L, Dive C (2013) Method validation of circulating tumour cell enumeration at low cell counts. BMC Cancer 13:415CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Crespo M, van Dalum G, Ferraldeschi R, Zafeiriou Z, Sideris S, Lorente D, Bianchini D, Rodrigues DN, Riisnaes R, Miranda S et al (2015) Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. Br J Cancer 112(7):1166–1174CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T et al (1997) Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57(2):314–319PubMedGoogle Scholar
  47. 47.
    Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66(5):2815–2825CrossRefPubMedGoogle Scholar
  48. 48.
    Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68(13):5469–5477CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1):11–22CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J et al (2012) Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov 2(11):995–1003CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Fedor HL, Lotan TL et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371(11):1028–1038CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, Lax S, Waldispuehl-Geigl J, Mauermann O, Lackner C et al (2013) Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res 73(10):2965–2975CrossRefPubMedGoogle Scholar
  53. 53.
    Dago AE, Stepansky A, Carlsson A, Luttgen M, Kendall J, Baslan T, Kolatkar A, Wigler M, Bethel K, Gross ME et al (2014) Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells. PLoS One 9(8):e101777CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Punnoose EA, Ferraldeschi R, Szafer-Glusman E, Tucker EK, Mohan S, Flohr P, Riisnaes R, Miranda S, Figueiredo I, Rodrigues DN et al (2015) PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients. Br J Cancer 113(8):1225–1233CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Beltran H, Jendrisak A, Landers M, Mosquera JM, Kossai M, Louw J, Krupa R, Graf RP, Schreiber NA, Nanus DM et al (2016) The initial detection and partial characterization of circulating tumor cells in neuroendocrine prostate cancer. Clin Cancer Res 22(6):1510–1519CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Department of Surgery, Oncology and Gastroenterology, Oncology SectionUniversity of PadovaPadovaItaly
  2. 2.Immunology and Molecular Oncology UnitIOV-IRCCSPadovaItaly

Personalised recommendations